Literature DB >> 18258245

Development of a high performance size exclusion chromatography method to determine the stability of Human Serum Albumin in a lyophilized formulation of Interferon alfa-2b.

Jin Qian1, Qinglin Tang, Bart Cronin, Robert Markovich, Abu Rustum.   

Abstract

Intron Powder for Injection is a lyophilized formulation of Interferon alfa-2b marketed for treatment of Hepatitis C and some cancer indications. Human Serum Albumin (HSA) is used as a lyoprotectant and cryoprotectant at 1.0 mg/mL in the product formulation. No stability-indicating method, which can quantitate HSA and its dimer or oligomer aggregates in the formulated product, has been published to date. This paper describes the development and validation of a stability-indicating high performance size exclusion chromatography (HPSEC) method for the assay of HSA and estimation of HSA related compounds in lyophilized Intron Powder for Injection. The method employs a YMC-Pack Diol-200 column (7.8 mm x 30 cm, 5 microm porous particles with 250 A pore size), UV detection at 214 nm, and a mobile phase of 0.1 M phosphate buffer at pH 7.0 with 0.1 M sodium sulfate. The mobiles phase runs in an isocratic mode at 1.0 mL/min and the total chromatographic run time is 30 min. The method was validated for specific, linearity, accuracy, sensitivity, and robustness. It was shown to be specific for HSA and HSA aggregates (dimer and oligomers) with a limit of quantitation of 0.0005 mg/mL or 0.05% of HSA label claim in the presence of active therapeutic protein, Interferon alfa-2b, and the other pharmaceutical excipients, glycine, sodium phosphate dibasic, sodium phosphate monobasic. The method is stability indicating and is suitable for assay of HSA from 0.0005 mg/mL to 1.5mg/mL. (0.05-150% of HSA label claim) and for estimation of HSA related aggregates (dimer, and oligomer) from 0.0005 mg/mL to 0.15 mg/mL (0.05-15% of HSA label claim). The method is robust for routine use in product quality control. The method was applied to the analysis of batches of lyophilized Intron Powder for Injection of low, middle and high strength from the beginning, middle and end of shelf-life. The results indicated that HSA is stable in the product through out its shelf-life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258245     DOI: 10.1016/j.chroma.2008.01.040

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  6 in total

1.  Antioxidant properties and instrumental quality characteristics of spray dried Pangasius visceral protein hydrolysate prepared by chemical and enzymatic methods.

Authors:  Mohammad Aman Hassan; Martin Xavier; Subodh Gupta; Binaya Bhusan Nayak; Amjad Khansaheb Balange
Journal:  Environ Sci Pollut Res Int       Date:  2019-02-04       Impact factor: 4.223

2.  Specific antioxidant properties of human serum albumin.

Authors:  Myriam Taverna; Anne-Lise Marie; Jean-Paul Mira; Bertrand Guidet
Journal:  Ann Intensive Care       Date:  2013-02-15       Impact factor: 6.925

3.  Study on the effect of solution conditions on heat induced-aggregation of human alpha interferon.

Authors:  Faranak Salmannejad; Nastaran Nafissi-Varcheh; Alireza Shafaati; Reza Aboofazeli
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

4.  Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule.

Authors:  Maurizio Baldassarre; Marco Domenicali; Marina Naldi; Maristella Laggetta; Ferdinando A Giannone; Maurizio Biselli; Daniela Patrono; Carlo Bertucci; Mauro Bernardi; Paolo Caraceni
Journal:  Sci Rep       Date:  2016-10-26       Impact factor: 4.379

Review 5.  Analytical Techniques for Structural Characterization of Proteins in Solid Pharmaceutical Forms: An Overview.

Authors:  Aljoša Bolje; Stanislav Gobec
Journal:  Pharmaceutics       Date:  2021-04-11       Impact factor: 6.321

6.  Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates.

Authors:  Paula Hong; Stephan Koza; Edouard S P Bouvier
Journal:  J Liq Chromatogr Relat Technol       Date:  2012-11-30       Impact factor: 1.467

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.